Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Antibe Therapeutics Inc(Pre-Merger)
ATBPF
Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,...
otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:ATBPF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
...
Next
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Jul 24, 2022 5:05pm
Busy with Acute ...
Wherever FDA approved chronic goes - it will be needed for all future chronic drugs too - and - it could circle back to future 20 year patents for pain as well. Never know. - IBD will need a
...more
(3)
•••
themagicbox
X
View Profile
View Bullboard History
Comment by
themagicbox
on Jul 24, 2022 3:40pm
RE:RE:RE:RE:RE:Keep this in mind LONGs ...
There is alot to unpack here so I'll take it one by one. The "liver history" that you are alluding to is likely the issue with paid participant from the ph1 trial. That individual was
...more
(174)
•••
Wriggles
X
View Profile
View Bullboard History
Comment by
Wriggles
on Jul 24, 2022 2:37pm
RE:RE:RE:RE:Keep this in mind LONGs ...
Thanks for your response Magic. I was referring more to your thoughts on why Oten would be used off label for chronic. I don't necessarily agree with this point of view. Oten is being
...more
(3)
•••
themagicbox
X
View Profile
View Bullboard History
Comment by
themagicbox
on Jul 24, 2022 2:05pm
RE:RE:RE:Keep this in mind LONGs ...
I thought it was self explanitory but sure. I am alluding to off label use i.e. it will be taken for longer than 2 weeks. w.r.t pain, in medicine "chronically" means > 3 months.
(174)
•••
Wriggles
X
View Profile
View Bullboard History
Comment by
Wriggles
on Jul 24, 2022 2:42am
RE:RE:Keep this in mind LONGs ...
" I promise once ATB-346 hits the market, it will be used "chronically" A intriging comment. Can you elaborate?
(3)
•••
themagicbox
X
View Profile
View Bullboard History
Comment by
themagicbox
on Jul 23, 2022 5:36pm
RE:Keep this in mind LONGs ...
Slight correction to your comment: *we have the best in class NSAID* Having said that, remember folks, perfection is the enemy of good. We dont have to be the "best", we just have to
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Jul 23, 2022 5:13pm
Keep this in mind LONGs ...
If you take a look at peak sales for 346 acute ... Let's assume it peaks around 2041 followed by a drop-off and then some years of modest recovery. I see peak annual sales around $7B-$9.5B
...more
(33)
•••
Inthepez
X
View Profile
View Bullboard History
Post by
Inthepez
on Jul 23, 2022 4:44pm
Wow the trolls are
On a rampage this Saturday. Dumpsters aka Czechcashings, stutters for brains, and stockings; all that's missing is chichi. Perhaps he'll chime In tmrrw lol
(55)
•••
StockingUp21
X
View Profile
View Bullboard History
Comment by
StockingUp21
on Jul 23, 2022 3:58pm
RE:RE:RE:Mmtr Troll
Losing money is so satisfying like responding to you're alias
(81)
•••
Stutters
X
View Profile
View Bullboard History
Post by
Stutters
on Jul 23, 2022 3:24pm
This is the dumbest thing i havw heard yet
you get Pez' razzie award momtroll
(81)
•••
Stutters
X
View Profile
View Bullboard History
Post by
Stutters
on Jul 23, 2022 3:22pm
I will buy at .80 not .62
sure thing momtroll
(81)
•••
Stutters
X
View Profile
View Bullboard History
Post by
Stutters
on Jul 23, 2022 3:20pm
Momtroll
we all know you are mugsy. Now Get back in your clowncar and vamoose
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Jul 23, 2022 3:04pm
RE:RE:Mmtr Troll
Amen Brother - Well said. Will continue to pick-up more until I'm satisfied - especially if scared holders are going to give it away at lower and lower prices. Always love a sale !!!!
(5)
•••
Mmmtroll
X
View Profile
View Bullboard History
Comment by
Mmmtroll
on Jul 23, 2022 2:01pm
RE:Mmtr Troll
well your wrong again but what else is new. you're wrong on both your points. Mgmt and me both bought at 60c. And I will continue to get more until I'm satisfied. Why don't you try posting
...more
(1093)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Jul 23, 2022 10:01am
It's not real (ERROR) haha
Antibe Therapeutics IncTSX Updated Jul 21, 2022 9:00 PM ATBPF0.480.00 (0.29%) Post-Market2.82 (587.50%)
Prev
...
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >